Experimental Treatment of Ebola Virus Disease with Brincidofovir.
Jake Dunning, Stephen B Kennedy, Annick Antierens, John Whitehead, Iza Ciglenecki, Gail Carson, Rupa Kanapathipillai, Lyndsey Castle, Rebecca Howell-Jones, Raul Pardinaz-Solis, Jennifer Grove, Janet Scott, Trudie Lang, Piero Olliaro, Peter W Horby, undefined RAPIDE-BCV trial team
PLoS One | Published : 2016
BACKGROUND: The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. METHODS AND FINDINGS: In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ≥50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10,..View full abstract
Awarded by World Health Organization
Awarded by Medical Research Council